LONDON, September 21, 2018 /PRNewswire/ --
Abingworth, the international investment group dedicated to life sciences, today announced that Brian Gallagher, PhD, will join Abingworth as a Partner based in the company's Boston office. Brian has more than 20 years of investing, business development, operational and R&D experience in both biotechnology and large pharmaceutical companies. He will work with the team in the London and Menlo Park offices to source and support deals across a wide range of therapeutic areas and stages of development from start-ups to late-stage venture capital investments.
Brian joins from SR One, the venture capital arm of GlaxoSmithKline (GSK), where he was a Partner and established the company's Boston office. Previously he was Senior Director of Corporate Development at Sirtris Pharmaceuticals where he played a key role in post-merger integration after the company's acquisition by GSK. Earlier in his career, Brian held roles in R&D at Alantos Pharmaceuticals and at Eisai. He holds a PhD in Organic Chemistry from the University of Michigan, is an inventor on over 25 patents and patent applications and is the senior author of a number of publications in prominent journals.
"We are delighted to welcome Brian to Abingworth's team," said Kurt von Emster, Managing Partner. "Boston is a key life science innovation centre and Brian's extensive investment experience, network, and business oversight will add significantly to the continued success and future of Abingworth."
"I am thrilled to join the Abingworth team at this exciting time," said Brian Gallagher. "Abingworth has a long and successful track record as a transatlantic firm and I look forward to driving the next stage of its growth, especially in the increasingly important life sciences hub in Boston."
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1.2 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life science sectors.
Supporting its portfolio companies with a team of 25 at offices in London, Menlo Park (California) and Boston, Abingworth has invested in 151 life science companies, leading to 65 IPOs and 46 mergers and acquisitions.
SOURCE Abingworth LLC